Red blood cell transfusions may be a life-sustaining therapy for individuals living with sickle cell disease, thalassemia and other conditions that affect the structure, chemistry, or production of red blood cells— often referred to as hemoglobinopathies. Clinical guidelines that provide evidence-based recommendations in these settings are important to inform optimal transfusion strategies for patients. Since 2018, Canadian Blood Services has supported the development of evidence-based guidelines on red blood cell transfusion in patients with hemoglobinopathies through its work with the

The Canadian Society for Transfusion Medicine (CSTM) annual conference, held in partnership with Canadian Blood Services and Héma-Québec, is taking place May 23-26 in Saskatoon. Each year, the CSTM conference provides opportunity for health-care professionals in transfusion medicine to share knowledge, learn about recent advancements in transfusion medicine, and connect with colleagues. Coinciding with the CSTM conference, Canadian Blood Services also hosts an annual Research Day event for invited members of our research and education network. In this second post in a series of blogs counting